Overview

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterise the pharmacokinetic profiles of non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), and the influence of the individual characteristics on the pharmacokinetic parameters in the Spanish population of HIV-infected subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Germans Trias i Pujol Hospital
Collaborators:
Fundacio Lluita Contra la SIDA
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Treatments:
Amprenavir
Atazanavir Sulfate
Darunavir
Efavirenz
Fosamprenavir
HIV Protease Inhibitors
Indinavir
Lopinavir
Nelfinavir
Nevirapine
Protease Inhibitors
Reverse Transcriptase Inhibitors
Ritonavir
Saquinavir
Tipranavir